Intelligent Therapeutics

Executive Summary

Intelligent Therapeutics is a private biotechnology company headquartered in Boston with operations in La Jolla, California, founded in 2017. The company focuses on developing innovative antibody and antibody-like molecules for the treatment of solid tumors and rare autoimmune diseases, while also pursuing opportunities in biosimilars and companion canine health. With a differentiated approach that leverages proprietary engineering platforms, Intelligent Therapeutics aims to address high-unmet-need indications. Despite being early-stage and privately held with no disclosed funding or pipeline specifics, the company's dual focus on human therapeutics and animal health positions it uniquely in the biotech landscape. Key risks include lack of clinical data, limited visibility into pipeline progress, and reliance on future financing.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead antibody candidate in solid tumors30% success
• Q2 2027Preclinical proof-of-concept data for rare autoimmune disease program45% success
• H1 2027Strategic partnership or licensing deal for biosimilar pipeline25% success